Park Ha Biological Technology Co., Ltd. (BYAH) Income Statement
BYAH FY2025 at a glance
Fiscal year ended October 31, 2025 · U.S. dollarsBYAH revenue and net income
Where BYAH's revenue goes
FY2025Each bar shows an amount and its share of revenue. BYAH kept −965.0% of revenue as net income.
BYAH profit margins
BYAH growth rates
to FY2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +6.0% | +9.6% | — | — |
| Gross profit | +9.0% | +19.1% | — | — |
| Operating income | −3,142.5% | — | — | — |
| Net income | −5,191.3% | — | — | — |
| EPS (diluted) | −1,637,500.0% | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BYAH quarterly EPS vs estimates
Park Ha Biological Technology beat the analyst EPS estimate in 0 of the last 1 quarters.
BYAH income statement
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $2.5M | $2.4M | $2.5M | $1.9M | $931,036 |
| Cost of revenue | $142,526 | $195,336 | $310,989 | $509,162 | $311,162 |
| Gross profit | $2.4M | $2.2M | $2.1M | $1.4M | $619,874 |
| Research & development | $238,184 | $36,714 | $30,881 | $60,671 | $52,009 |
| Sales, general & admin | $26.1M | $1.2M | $784,570 | $1.1M | $751,816 |
| Total operating expenses | $26.5M | $1.4M | $967,559 | $1.2M | $1.1M |
| Operating income | −$24.1M | $793,714 | $1.2M | $197,024 | −$500,976 |
| Interest income | $6,097 | $783 | $1,590 | $263 | $167 |
| Interest expense | $41 | $0 | $0 | $194 | $1,194 |
| Income before taxes | −$24.1M | $793,421 | $1.2M | $190,010 | −$484,958 |
| Income taxes | $280,646 | $314,860 | $329,527 | −$1,288 | — |
| Net income | −$24.4M | $478,561 | $852,042 | $191,298 | −$484,958 |
| EBITDA | −$24.0M | $816,107 | $1.2M | $220,695 | −$444,758 |
| EPS (diluted) | −$327.48 | $0.02 | $0.85 | — | — |
| Gross margin | 94.4% | 91.8% | 87.4% | 73.5% | 66.6% |
| Operating margin | −956.5% | 33.3% | 48.0% | 10.3% | −53.8% |
| Net margin | −965.0% | 20.1% | 34.6% | 10.0% | −52.1% |
| Apr '26 | Jan '26 | Oct '25 | Jul '25 | Apr '25 | |
|---|---|---|---|---|---|
| Revenue | $1.3M | $628,845 | $1.3M | $642,823 | $1.2M |
| Cost of revenue | $141,000 | $22,860 | $177,887 | $42,013 | $58,500 |
| Gross profit | $1.1M | $605,985 | $1.1M | $600,810 | $1.2M |
| Research & development | $138,618 | $69,309 | $212,097 | $106,048 | $26,087 |
| Sales, general & admin | — | $1.0M | — | $2.7M | — |
| Total operating expenses | $2.1M | $1.1M | $5.5M | $2.8M | $20.9M |
| Operating income | −$962,547 | −$481,274 | −$4.4M | −$2.2M | −$19.7M |
| Interest expense | $4 | — | $21 | — | $20 |
| Income before taxes | −$929,502 | −$464,751 | −$4.4M | −$2.2M | −$19.7M |
| Income taxes | −$11,220 | −$5,610 | $101,700 | $50,850 | $178,946 |
| Net income | −$918,282 | −$459,141 | −$4.5M | −$2.3M | −$19.8M |
| EBITDA | −$867,265 | −$433,633 | −$4.3M | −$2.2M | −$19.6M |
| EPS (diluted) | — | — | — | −$0.74 | — |
| Gross margin | 88.8% | 96.4% | 86.2% | 93.5% | 95.3% |
| Operating margin | −76.5% | −76.5% | −344.8% | −344.8% | −1,591.0% |
| Net margin | −73.0% | −73.0% | −352.3% | −352.3% | −1,600.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in BYAH's financial statements (latest annual report filed October 31, 2025); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BYAH financial results
In fiscal year 2025 (ended October 31, 2025), Park Ha Biological Technology reported revenue of $2.5 million, up 6.0% from the year before. It had a net loss of $24.4 million, a net profit margin of −965.0%. Diluted earnings per share came to −$327.48.
See the BYAH stock overview for the latest quote and news, or the BYAH chart for price history and technical indicators.
BYAH income statement FAQ
What is Park Ha Biological Technology's annual revenue?
Park Ha Biological Technology reported total revenue of $2.5 million for fiscal year 2025, which ended on October 31, 2025. That was up 6.0% from $2.4 million the previous year.
Is Park Ha Biological Technology profitable?
No. Park Ha Biological Technology reported a net loss of $24.4 million in fiscal 2025, a net profit margin of −965.0%; its operating margin was −956.5%.
What is Park Ha Biological Technology's gross margin?
Park Ha Biological Technology's gross margin was 94.4% in fiscal 2025: for every $100 of revenue, Park Ha Biological Technology kept $94 after the direct cost of its products and services.
How much does Park Ha Biological Technology spend on research and development?
Park Ha Biological Technology spent $0.2 million on research and development in fiscal 2025, 9.4% of revenue.
What are Park Ha Biological Technology's earnings per share?
Park Ha Biological Technology earned $-327.48 per diluted share in fiscal 2025, compared with $0.02 a year earlier.
When does Park Ha Biological Technology's fiscal year end?
Park Ha Biological Technology's fiscal year ends in October. The latest annual report covers the year ended October 31, 2025 and was filed on October 31, 2025.